ENANTA PHARMACEUTICALS INC
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
ENTA$11.47+4.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except per share data)
| March 31, | September 30, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $60,213 | $37,233 |
| Short-term marketable securities | 133,162 | 210,953 |
| Accounts receivable | 6,792 | 6,646 |
| Prepaid expenses and other current assets | 8,857 | 12,413 |
| Income tax receivable | 33,836 | 31,999 |
| Short-term restricted cash | — | 608 |
| Total current assets | 242,860 | 299,852 |
| Property and equipment, net | 37,572 | 32,688 |
| Operating lease, right-of-use assets | 39,103 | 40,658 |
| Long-term restricted cash | 3,360 | 3,360 |
| Other long-term assets | 98 | 94 |
| Total assets | $322,993 | $376,652 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $4,756 | $8,002 |
| Accrued expenses and other current liabilities | 8,314 | 13,547 |
| Liability related to the sale of future royalties | 30,681 | 34,462 |
| Operating lease liabilities | 2,196 | 1,524 |
| Total current liabilities | 45,947 | 57,535 |
| Liability related to the sale of future royalties, net of current portion | 125,379 | 134,779 |
| Operating lease liabilities, net of current portion | 56,536 | 53,943 |
| Series 1 nonconvertible preferred stock | 1,350 | 1,350 |
| Other long-term liabilities | 243 | 231 |
| Total liabilities | 229,455 | 247,838 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Common stock; $0.01 par value per share, 100,000 shares authorized; 21,377 and 21,194 shares issued and outstanding at March 31, 2025 and September 30, 2024, respectively | 214 | 212 |
| Additional paid-in capital | 461,522 | 451,340 |
| Accumulated other comprehensive (loss) gain | (224) | 302 |
| Accumulated deficit | (367,974) | (323,040) |
| Total stockholders' equity | 93,538 | 128,814 |
| Total liabilities and stockholders' equity | $322,993 | $376,652 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.